Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2008 2
2011 1
2012 4
2013 5
2014 4
2015 4
2016 2
2017 6
2018 8
2019 14
2020 12
2021 33
2022 17
Text availability
Article attribute
Article type
Publication date

Search Results

101 results
Results by year
Filters applied: . Clear all
Page 1
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.
Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, Al Khatib HA, Coyle P, Ayoub HH, Al Kanaani Z, Al Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Al Kuwari MG, Al Romaihi HE, Butt AA, Al-Thani MH, Al Khal A, Bertollini R, Abu-Raddad LJ. Chemaitelly H, et al. N Engl J Med. 2021 Dec 9;385(24):e83. doi: 10.1056/NEJMoa2114114. Epub 2021 Oct 6. N Engl J Med. 2021. PMID: 34614327 Free PMC article.
Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination.
Butt AA, Nafady-Hego H, Chemaitelly H, Abou-Samra AB, Khal AA, Coyle PV, Kanaani ZA, Kaleeckal AH, Latif AN, Masalmani YA, Bertollini R, Raddad LJA. Butt AA, et al. Among authors: chemaitelly h. Int J Infect Dis. 2021 Sep;110:353-358. doi: 10.1016/j.ijid.2021.08.008. Epub 2021 Aug 8. Int J Infect Dis. 2021. PMID: 34375762 Free PMC article.
Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections.
Abu-Raddad LJ, Chemaitelly H, Bertollini R; National Study Group for COVID-19 Epidemiology. Abu-Raddad LJ, et al. Among authors: chemaitelly h. N Engl J Med. 2021 Dec 23;385(26):2487-2489. doi: 10.1056/NEJMc2108120. Epub 2021 Nov 24. N Engl J Med. 2021. PMID: 34818474 Free PMC article. No abstract available.
Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar.
Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, Coyle P, Al Kanaani Z, Al Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Al Kuwari MG, Butt AA, Al Romaihi HE, Al-Thani MH, Al Khal A, Bertollini R. Abu-Raddad LJ, et al. Among authors: chemaitelly h. JAMA. 2021 Nov 16;326(19):1930-1939. doi: 10.1001/jama.2021.19623. JAMA. 2021. PMID: 34724027 Free PMC article.
Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.
Abu-Raddad LJ, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Malek JA, Coyle P, Ayoub HH, Al Kanaani Z, Al Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Al Khal A, Butt AA, Bertollini R. Abu-Raddad LJ, et al. Among authors: chemaitelly h. J Travel Med. 2021 Oct 11;28(7):taab083. doi: 10.1093/jtm/taab083. J Travel Med. 2021. PMID: 34050372 Free PMC article. No abstract available.
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, AlMukdad S, Coyle P, Ayoub HH, Al Kanaani Z, Al Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Al Kuwari MG, Al Romaihi HE, Butt AA, Al-Thani MH, Al Khal A, Bertollini R, Abu-Raddad LJ. Tang P, et al. Among authors: chemaitelly h. Nat Med. 2021 Dec;27(12):2136-2143. doi: 10.1038/s41591-021-01583-4. Epub 2021 Nov 2. Nat Med. 2021. PMID: 34728831
Protection against the Omicron Variant from Previous SARS-CoV-2 Infection.
Altarawneh HN, Chemaitelly H, Hasan MR, Ayoub HH, Qassim S, AlMukdad S, Coyle P, Yassine HM, Al-Khatib HA, Benslimane FM, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Tang P, Abu-Raddad LJ. Altarawneh HN, et al. Among authors: chemaitelly h. N Engl J Med. 2022 Mar 31;386(13):1288-1290. doi: 10.1056/NEJMc2200133. Epub 2022 Feb 9. N Engl J Med. 2022. PMID: 35139269 Free PMC article. No abstract available.
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy.
Abu-Raddad LJ, Chemaitelly H, Coyle P, Malek JA, Ahmed AA, Mohamoud YA, Younuskunju S, Ayoub HH, Al Kanaani Z, Al Kuwari E, Butt AA, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Yassine HM, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Al Khal A, Bertollini R. Abu-Raddad LJ, et al. Among authors: chemaitelly h. EClinicalMedicine. 2021 May;35:100861. doi: 10.1016/j.eclinm.2021.100861. Epub 2021 Apr 28. EClinicalMedicine. 2021. PMID: 33937733 Free PMC article.
101 results